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Preferences for the delivery of community pharmacy services to help 
manage chronic conditions 
 
Abstract 
 
Background: To optimise positive outcomes, the design of new pharmacy services should 
consider the preferences of consumers with chronic condition(s) and their carers. 
Objectives: (i) To evaluate the relative importance of community pharmacy service 
characteristics, from the perspective of consumers with chronic condition(s) and carers; (ii) 
To compare consumer and carer preferences to health professional beliefs about ideal service 
characteristics for consumers.  
Method: A discrete choice experiment was completed by consumers with chronic 
condition(s) and/or carers (n=602) and health professionals (n=297), recruited from four 
regions in Australia. Participants were each randomised to one survey version containing four 
(from a total 72) different choices between two new pharmacy services. Consumer and carer 
participants were also given an ‘opt out’ alternative of current service. Each service was 
described using six attributes related to pharmacy service characteristics: continued 
medicines supply, continuity and coordinated care, location, medication management, 
education and information, and cost.  
Results: Consumers and carers placed highest priority on continued medicines supply by a 
pharmacist for regular and symptom flare up medicines (100 priority points), a pharmacy 
located within a ‘one-stop’ health centre (61 points) and home delivery of medicines (52 
points). Although continued medicines supply was most important for consumers and carers, 
pharmacy location was perceived by health professionals to be the most important 
characteristic for consumers. Participants were less inclined to choose new services if their 
current pharmacy offered high quality services that were person-centred, easy to access and 
responsive to their needs. Younger, more highly educated and employed participants, and 
those with established condition(s) were more likely to choose new services. 
Conclusions: Person-centred care is a fundamental tenet for pharmacy services. The provision 
of continued medicines supply (e.g. through pharmacist prescribing), convenient and 
coordinated care delivered through a one stop health centre, and home delivery of medicines, 
should be prioritised when planning pharmacy services to best assist consumers to manage 
chronic conditions.  
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Article Synopsis: 
 
This study employed a discrete choice experiment to evaluate the preferences of consumers 
with chronic condition(s) and unpaid carers for pharmacy service characteristics in Australia, 
and to compare consumer and carer preferences to health professional beliefs about ideal 
service characteristics. It found that person-centred care is a fundamental tenet for pharmacy 
services. The provision of continued medicines supply (e.g. through pharmacist prescribing), 
convenient and coordinated care delivered through a one stop health centre, and home 
delivery of medicines, should be prioritised when planning pharmacy services to best assist 
consumers to manage their chronic conditions. 
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Background 
 
The role of the pharmacist and community pharmacy has evolved from being 
principally centred on medicines supply to include a broader focus on medicines 
management, adherence support and promoting the judicious, appropriate, safe and 
efficacious use of medicines in the community.1, 2 Pharmacists are amongst the most 
frequently visited, available and trusted health professionals in the community setting.3-6 The 
accessibility of pharmacy for most consumers reinforces its potential to promote general 
community health, but also self-management and optimal use of medicines by those with 
chronic conditions.   
 
 Pharmacy services other than dispensing have been reported to be beneficial in some 
settings to assist the management of selected chronic condition(s), leading to improved 
clinical outcomes, quality of life (QoL) and reduced healthcare utilisation.7-10  Services that a 
pharmacist could potentially offer to help consumers and their carers effectively manage 
chronic conditions include medication reviews, education and information, safety monitoring 
through reporting adverse drug reactions or interactions or both, supporting compliance 
through dose administration aids, and liaising with a person’s General Practitioner (GP) and 
other health providers as part of a care plan.11 Perhaps more contentiously, in selected 
countries, pharmacists can also prescribe in a range of models across varying scopes of 
practice.12, 13  
 
Despite the potential benefits of pharmacy-led services, there is little evidence 
available from the consumer perspective about the acceptability or preferred design of new or 
innovative pharmacy services.14 The few studies that have examined consumer preferences 
have reported some support for extended pharmacy roles, such as prescribing in England and 
Scotland, where pharmacist prescribing is now comparatively well established.15, 16 One 
Australian study reported support for the delivery of specialised asthma services through 
community pharmacy.17  
 
In other areas, it is now recognised that to provide optimal benefit for consumers and 
carers and be responsive to their needs, the design of new services should consider the 
preferences of consumers. Indeed, the benefits of considering consumer preferences in 
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healthcare reform and service design have been widely recognised.18-20 Consumers bring a 
unique perspective, which can promote the relevance, responsiveness, quality and safety of 
health service delivery. Furthermore, if consumers are engaged in the development of 
services, it is more likely that they will access these services, form partnerships around their 
care, and adhere to recommended  management plans, ultimately leading to improved health 
outcomes.21  This is particularly important for populations with unique needs, such as young 
people who experience barriers to healthcare access and unmet health needs that youth-
friendly pharmacy services could address.22, 23  There is a clear need for a greater 
understanding of preferred pharmacy services from the consumer perspective, to harness the 
opportunity for pharmacy to develop innovative health and medicines services to benefit the 
community.       
 
This study is part of a wider project focused on consumers’ perceptions of chronic 
conditions, treatment burden, and the engagement of community pharmacy in chronic 
condition management. The primary aim of this sub-study was to examine the relative 
importance of different pharmacy service characteristics for consumers with chronic 
condition(s) and carers of people with these condition(s), and the trade-offs that are made 
when choosing between pharmacy services. A secondary aim was to investigate the 
similarities and differences between consumer and carer preferences, and the perceptions of 
health professionals about consumer preferences. Given that health professional perceptions 
are likely to affect the design and delivery of services, agreement between these parties is 
critical. Several studies have investigated pharmacist preferences for an extended role,24, 25 
but none have directly compared the preferences of consumers and perceptions of health 
professionals for the preferred characteristics of pharmacy services.  
 
 
Methods 
 
A discrete choice experiment (DCE) was employed to elicit preferences for pharmacy 
services.  The DCE is a choice-based preference elicitation method, with a theoretical 
foundation in Random Utility Theory and Lancaster’s Theory of Value.26-28 It is an 
established method for assessing preferences for healthcare and the trade-offs participants are 
willing to make between different desirable characteristics of a healthcare service, including 
in contexts related to the management of chronic conditions.29, 30 The method has been 
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applied previously to elicit preferences related to pharmacy and medicines use,14 including 
measuring consumer preferences for self-care or professional advice for minor illness,31 and 
examining the strength of preference of community pharmacists for existing and potential 
new roles.17, 25 
 
DCEs typically involve a questionnaire containing a series of choices between two or 
more alternative products or services. . Each alternative product or service is composed of 
different characteristics or “attributes”, and in turn each attribute can take on several layers 
(referred to as “levels”). The levels of the attributes for each alternative are varied 
systematically across choices and for each choice set, participants select the alternative they 
prefer. The relative importance of improvements in the attributes and the trade-offs 
individuals make when choosing one alternative over another are estimated through analysis 
of the choice data. 
 
(i) Identification and selection of attributes and levels 
 
In the DCE, each participant was asked to consider four hypothetical choice sets and 
each choice set was composed of two different new pharmacy services. The attributes and 
levels used to describe each new service were developed based on extensive qualitative 
research involving 97 interviews with consumers and carers,32-34 followed by 26 focus groups 
with consumers, carers and health professionals, during which the nominal group technique 
was used to rank priorities for pharmacy service delivery.35, 36 Findings of these formative 
studies suggested six overarching themes were highly and consistently prioritised by 
participants, and were potentially meaningful to a community pharmacy service model. These 
themes were developed into six related pharmacy service characteristics or “attributes”, each 
described by between two and four levels. The attributes used to describe the hypothetical 
new services represented the extent to which a pharmacist could provide continued medicines 
supply (e.g. through repeat prescribing); whether pharmacy staff could direct individuals for 
advice from other service or other services were provided at the pharmacy; where the 
pharmacy was located; how medicines could be collected; how a pharmacist could be 
accessed for review of advice; and an indicative average out of pocket cost for the service per 
month (in addition to the cost of medicines). The themes and final selected attributes and 
levels are provided in Table 1. 
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 Table 1 about here 
 
 
(ii) Statistical Design 
 
The attributes and levels in Table 1 in combination describe a full factorial design of 
216 (i.e. 4*(3^3)*2) different pharmacy services, in 23,220 different pairs.37 Experimental 
design theory was used to select a manageable number of pairs to present to participants, 
whilst maximising the efficiency (i.e. precision) of the preference estimates elicited from the 
choices.29, 37 The level for each attribute was varied across alternative services according to a 
main effects fractional factorial experimental design, estimated using NGENE software using 
the Street and Burgess design approach.38, 39 This ensured optimal statistical power for the 
design, whilst maintaining orthogonality in the variation of attribute levels, such that the main 
effects for the attribute levels could be independently estimated in the model. 
 
The design identified 72 choice sets, with each set presenting a choice between two 
alternative pharmacy services. To ensure the number of choices faced by each participant was 
manageable, these were divided into 18 blocks of four choice sets, with participants 
randomised to one of the 18 blocks. An indicative choice set for consumers and carers is 
shown in Figure 1. To increase realism, consumer and carer participants were given a second 
level “opt out” option for each choice set; they were asked to indicate whether they would 
take their preferred new service (i.e. service A or B), or would in reality continue to use their 
current pharmacy service. This question was not relevant for health professionals, who were 
only asked to respond according to the new pharmacy service they thought consumers would 
prefer. Consumer and carer participants who opted out of a new service on one or more 
occasions were invited to explain their reasons for doing so. 
 
In addition to the choice sets, participants were asked questions related to their (i) 
socio-demographic characteristics, (ii) use of primary healthcare services and medicines, (iii) 
health status (including generic health-related QoL assessed using the EQ-5D-3L),40 (iv) 
treatment burden (consumers and carers only), using an instrument developed by Tran and 
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colleagues,41 and (iii) professional role (health professionals only). The results related to 
treatment burden and QoL will be presented elsewhere. 
 
 
Figure 1 about here 
 
(iii) Study participants and data collection 
 
Ethical approval for the study was provided by a University and a Health Service 
Human Research Ethics Committee (PHM/12/11/HREC; HREC/13/QPAH/605). The DCE 
was administered to two samples; (i) a sample of adults with one or more chronic 
conditions(s) and/or adult unpaid carers of people with chronic condition(s); and (ii) a sample 
of health professionals (including pharmacists, doctors, nurses and allied health practitioners) 
who would commonly encounter people with chronic conditions in the community. A sample 
size of 600 consumers and carers and 250 health professionals was targeted based on 
representation of the adult population with chronic conditions in Australia and the anticipated 
precision of estimates from the DCE analysis. For a population of approximately 17 million 
adults, with an estimated 75% of all Australians or 85% of those aged 15 years or over 
reporting one or more chronic condition(s),42 a completed sample of 600 has a margin of 
error of 4%.43 There is no consensus on appropriate sample sizes for DCE tasks to give 
precise estimates, and sample sizes are based on rules of thumb.44, 45 One commonly applied 
rule of thumb suggests that for the proposed DCE design, a minimum sample size of 250 is 
required.44 The targeted consumer and carer sample size of 600 substantially exceeds that 
used for the majority of DCEs in healthcare,29 and would be expected to support the greater 
number of analyses to explore associations between preference and participant characteristics 
of interest.46 
 
Participants were recruited from four regions in Australia chosen for their 
socioeconomic, cultural and geographic diversity; Logan Beaudesert and the Mount Isa and 
North West region (Queensland), Northern Rivers (New South Wales) and the greater Perth 
area (Western Australia). Consumers and carers residing in these areas were invited to 
participate if they had one or more ongoing medical condition(s) and/or perceived themselves 
to be a carer of someone with one or more ongoing medical condition(s). Recruitment 
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occurred via local newspaper advertisements, flyers placed in and distributed by pharmacies, 
medical centres, other health clinics, community centres and via consumer health 
organisations in these regions. To ensure coverage of participants who were not accessing 
health services, recruitment also occurred through face-to-face contact distribution of flyers 
outside supermarkets and at markets. To ensure diversity, Aboriginal and Torres Strait 
Islander peoples and individuals from culturally and linguistically diverse backgrounds were 
targeted through community groups, health centres and non-government organisations. 
Health professionals were invited to participate if they resided or worked in one of the four 
areas, and perceived themselves to have a role that focussed on providing health services to 
people with chronic condition(s) in the community. 
 
A total of 849 consumers and carers and 412 health professionals expressed an 
interest and were invited to participate in the DCE survey. The DCE was predominantly 
administered as a computer-assisted telephone interview (CATI) by a third party research 
company on behalf of the research team. A CATI survey approach was chosen in an attempt 
to maximise both the rate and completeness of response, as compared to alternative 
approaches, such as mail or internet based administration.47 Surveys and study materials were 
mailed to participants, who were then contacted one to two weeks later and invited to 
participate in a telephone interview. To maximise the diversity of the sample and ensure 
everyone who wanted to participate was able to do so, a minority of interviews were also 
conducted face-to-face by the research team. Face-to-face delivery was used particularly for 
groups that might be considered difficult to reach via the telephone or who preferred face-to-
face interview, including culturally and linguistically diverse consumer and carer participants, 
health professionals and those identifying with an Aboriginal or Torres Strait Islander 
background. Although the approach was flexible and accommodated participant 
requirements, surveys were always completed individually. Each participant was provided a 
gift voucher to compensate for their time (i.e. AU$50 for consumer and carer participants and 
AU$30 for health professionals, as their survey was shorter).   
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The DCE instrument was piloted extensively, initially face-to-face in a convenience 
sample of adults (including consumer, carer and health professional participants). The 
instrument was refined, and then further piloted in 36 adults with chronic condition(s) via 
CATI, before the main data collection was undertaken between October 2013 and January 
2014. 
 
(iv) Data analysis 
 
Data were analysed using regression analysis, in which the discrete choice formed the 
dependent variable, and the attribute levels presented for each alternative were specified as 
independent variables to explain choice. The analysis for consumer and carer data was based 
on the choice between a new service or their current service (A, B or current). In addition, 
qualitative reasons given for opting out of a new service were analysed thematically. The 
analysis of health professional data was based on the choice question allowing participants to 
indicate which new service (A or B) they considered their consumers would prefer. 
 
The choice data were analysed in NLogit statistical software using mixed logit models 
(MXL).48  The MXL model is a generalised analytic approach that allows for potential 
correlation in the multiple choice responses provided by any one individual as well as across 
alternatives in the choice set, and also models preference heterogeneity by allowing 
preferences estimated by the model to vary across the individuals in the sample. 29, 49  For 
each attribute level, the model estimated a mean (i.e. average) preference weight for the 
sample, indicating its relative importance. Participant characteristics were entered into the 
model to explain the variation in preference around the sample mean (i.e. preference 
heterogeneity). 
 
Model specification 
 
The utility functions for the new pharmacy services (A and B) were specified as a 
linear additive function of the main effects for each attribute level. For the consumer and 
carer model, the utility function for the current service was specified to include an alternative 
specific constant. All attribute levels were initially specified using effects coding.50 
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Preliminary analyses suggested that the levels of the cost attribute exhibited linear effects; 
therefore, the cost attribute was coded continuously. The MXL model was initially specified 
with all attribute level effects assumed to be random and following a normal distribution.49  
Attribute levels for which the standard deviation was not significant (p≤0.2, chosen as a 
cautious level given this provided the foundation for the next analytic step), suggesting no 
substantial preference heterogeneity for that attribute level, were then specified to be fixed 
and the model was re-estimated. All preliminary models were estimated using 25 Halton 
draws; the final model was then estimated using 1000 Halton draws.49 
  
 
Modelling preference heterogeneity 
 
Participant characteristics (Tables 2 and 3) were entered into the MXL model, to 
investigate the extent to which they explained any preference heterogeneity. All participant 
characteristics were specified as effects coded variables. There was a small proportion (≤3%) 
of missing data for some characteristics; missing data were coded as zero. This approach 
assumes the sample mean parameter estimate for a participant with missing data, allowing the 
retention of all choice observations in the model. A backward step regression approach was 
used, whereby all characteristics were entered in the model, and characteristics were then 
systematically removed with the least significant in explaining heterogeneity for any attribute 
level being removed first. The stepped process retained only those participant characteristics 
that were significant in explaining heterogeneity for one or more attribute levels at the 
significance level of p≤0.2, p≤0.1, p≤0.05 in turn. Only those characteristics that significantly 
explained preference heterogeneity at the 5% level were retained in the final regression 
model (p≤0.05).  
 
Comparison between consumer and carer priorities and health professional perceptions of 
consumer priorities 
 
The size of the coefficients in the preference models indicate the relative importance 
of different pharmacy services. The model coefficients were weighted such that the most 
preferred service improvement for each model was given 100 points, and the other 
improvements were given a lesser number of points in proportion to their relative importance 
for that sample. For each model, this was achieved for effects coded attributes by: (i) 
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selecting the attribute for which there was the greatest statistically significant marginal utility 
associated with an improvement between any two levels (k); (ii) estimating the marginal 
utility for a gain from the least preferred level (R) to the most preferred level (L) (i.e. the 
difference in coefficients for these levels); (iii) assigning 100 points to this marginal utility 
gain; (iv) estimating points (Points KL) for a gain between levels for each of the other 
attributes (K≠k) as a relative proportion of 100  points according to Equation 1:  
 
Equation 1: 
 =
(							)
	
∗ 100		 [For all K≠k] 
 
For the cost attribute, points were assigned for the marginal effect associated with a $1 cost 
reduction per month by using the coefficient for cost as the numerator in Equation 1.     
 
Results 
 
(1) Participant characteristics 
 
The DCE survey was completed by 602 consumer and carer participants (70.9% 
response rate) and 297 health professional participants (72.1% response rate). Data about the 
source of recruitment was available for 89% (536/602) consumers and carers who completed 
the survey. The most successful recruitment strategies were direct promotional activities by 
research team members in shopping centres and markets (33%), followed by flyer 
distribution by health providers and at health clinics and centres (21%). Data about 
recruitment sources was available for all 297 health professional participants, with the 
majority  (61%) recruited via direct promotional activities conducted by the research team at 
lunch-time meetings, visits to health services and clinics and pharmacies located in shopping 
centres and email invitations sent to professional networks. The majority of surveys (548, 
91.0% consumers and carers and 180, 60.6% health professionals) were conducted by CATI, 
with the remainder conducted face-to-face. Tables 2 and 3 summarise the characteristics of 
consumer and carer, and health professional participants respectively. 
 
 
Tables 2 and 3 about here  
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(2) Responses to the DCE choice sets 
 
A similar number of participants (between 4.8% and 6.1% of each sample) completed 
each of the 18 survey versions. Data analysis for the consumer and carer preference model 
was based on 2,396 choices, consisting of four choices made by each of 602 consumer and 
carer participants (less 12 missing choices across 5 individuals).  Data analysis for the health 
professional model was based on 1188 choices, consisting of four choices made by each of 
the 297 health professional participants. 
 
(3) Uptake of a new service versus retention of current service 
 
The consumer and carer participants chose a new pharmacy service (i.e. service A or 
B) for 855 (35.7%) of all choices. Nearly one quarter of participants (n=131, 21.8%) chose 
one of the new services in all four scenarios, whilst the majority of consumers and carers 
“opted out” of a new service and chose to remain with their current pharmacy service in at 
least one scenario. Almost half the participants (n=288; 47.8%) selected their current 
pharmacy service in all four scenarios. Thus, there was evidence of a tendency for extreme 
patterns of choice, either favouring the current pharmacy or favouring new services in every 
choice scenario. 
 
 
On average, participants who opted out of at least one scenario provided 1.9 reasons 
(range 1 to 6 reasons) for choosing their current pharmacy service. In total, 907 reasons were 
supplied by participants who opted out of at least one scenario; the most common reasons for 
opting out are given in Table 4. In summary, when clustered into broader themes, three main 
drivers of the choice to retain a current pharmacy service emerged; namely, person-centred 
services, such as a long-term personal and respectful relationship with pharmacy staff 
(n=349; 38.5% of all reasons); easy access to pharmacy services (i.e., speed, convenience, 
location and low cost; n=259; 28.6%); and continuous reliable supply of medication and 
availability of timely, quality advice about medicines and symptoms (n=242; 26.7%). 
Participants often commented that they would not consider new pharmacy services if it meant 
a change to one or more of these qualities. Only a small number of participants held strong 
traditional views about the respective roles of GPs and pharmacists. 
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Table 4 about here 
 
 
(4) Consumer and carer preferences for the characteristics of pharmacy services 
 
Six of the consumer and carer characteristics included in the DCE choice sets 
significantly explained preference heterogeneity (p≤0.05) in the preliminary MXL models, 
and were therefore included in the final MXL model (Table 5). The final model had a pseudo 
R2 of 0.423, representing a good fit for a discrete choice model.49  
 
 
Table 5 about here 
 
 
Consistent with the raw choice data, on average there was a strong propensity for 
consumers and carers to select their current service, rather than a new service. This is 
indicated by the large and highly significant constant associated with the current service 
(β=2.048; p≤0.001). Four of the six attributes significantly influenced choice of pharmacy 
service. Participants preferred to have access to a pharmacist for ongoing supply of regular 
medicines and for medicines they have used before for symptom flare ups, rather than having 
access to a doctor alone (p≤0.001). Having access to ongoing supply from a pharmacist for 
regular medicines tended to be preferred over access to supply from a doctor alone, but this 
did not reach statistical significance (p=0.725). In terms of location, on average, a one-stop 
health centre was preferred over a pharmacy near a participant’s home or workplace, but a 
pharmacy near home/work was preferred to a pharmacy near their GP practices (p=0.005). 
On average, participants preferred the availability of home delivery as an option over having 
face-to-face pick up of medicines alone (p≤0.001). They also preferred having face-to-face 
pick up over other types of collection that do not involve going into the pharmacy e.g. by 
“drive thru” in addition to face-to-face (p=0.025). Finally, participants preferred a pharmacy 
service that was available at a lower cost (p=0.002). 
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Two attributes did not have a significant impact on choices, namely access to other 
health professionals and access to the pharmacist. First, choices were not influenced by the 
prospect of having access to other health professionals employed in the pharmacy or 
pharmacy staff directing individuals to other services (p=0.111). Second, choices were not 
influenced by the availability of the pharmacist for medicines review or advice (i.e. access to 
a pharmacist in the pharmacy but without having to ask, additional accessibility by 
phone/email/internet, or by appointment at home, or a pharmacist who remained in the 
dispensary but responded when asked; p=0.183 to 0.416). 
 
Substantial variation was observed in the strength of preference across the sample for 
the choice of current service over a new service, and for the impact of the attributes related to 
continued medicines supply and cost. This variation is indicated by significant standard 
deviations (p≤0.01) that are large relative to the size of the mean for the related parameter 
(Table 5). There were a number of participant characteristics that significantly explained the 
variation in preference for each of these attributes (p≤0.05). Older participants, those who 
usually visit the same pharmacy, those with a lower level of education, those with a recent 
diagnosis of a chronic condition, and those from the Greater Perth region were more likely to 
choose their current service than their counterparts, all else equal. Younger participants and 
those in employment were less likely to choose their current service than their counterparts. 
Participants taking medicines more frequently during the day were significantly more likely 
to value access to a pharmacist for continued supply of their regular medicines rather than 
relying on a doctor alone (p=0.008). Conversely, those recently diagnosed with a chronic 
condition were less likely to value access to a pharmacist for continued supply of regular 
medicines (p=0.040). Participants who were employed were significantly more averse to cost, 
while those from Mt Isa and North West Queensland region were less averse to cost (p≤0.01).  
 
 
(5) Health professional perception of consumer preferences  
 
For the health professional preference model, five participant characteristics 
significantly explained perceived preference heterogeneity (p≤0.05) in the preliminary MXL 
models and were therefore included in the final MXL model. The final model had a pseudo 
R2 of 0.235, representing a moderate fit for a discrete choice model.49 The final model is 
presented in Table 6. 
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Table 6 about here 
 
 
Overall, the perceptions of health professionals were substantially consistent with the 
preferences of consumers and carers. On average, a one-stop health centre was expected to be 
preferred over a pharmacy near a consumer or carer’s home/work, and a pharmacy near 
home/work was expected to be preferred to a pharmacy near to their GP practice (p≤0.001). 
Participants expected consumers to prefer the availability of home delivery as an option over 
having face-to-face pick up of medicines alone (p≤0.001). There was a trend for participants 
to expect consumers to value the option to collect medicines without going into the 
pharmacy, e.g. through “drive thru” more than face-to face collection alone; however, this did 
not reach statistical significance at the 5% level (p=0.085). Such a trend was inconsistent 
with the preferences of consumers and carers, who preferred having face-to-face pick up 
alone over the availability of collection without going into the pharmacy, e.g. by “drive thru” 
in addition to face-to-face. Four attributes did not have a significant impact on perceptions of 
consumer choice (p>0.05): continued medicines supply, managing ongoing conditions, 
medicines review or advice, and average cost per month.  
 
Substantial variation was observed across the health professional sample in the extent 
to which the attributes related to continued medicines supply, managing an ongoing 
condition, pharmacy location and cost impacted choice (Table 6). There were a number of 
participant characteristics that significantly explained the variation in perceptions between 
participants for each of these characteristics (p≤0.05). First, participants who had been in 
their profession for less than five years were more likely to indicate their consumers would 
value access to a pharmacist for ongoing supply of regular medicines and for medicines they 
have used before for symptom flare ups, rather than having access to a doctor alone 
(p=0.009). Participants who were not a consumer or carer themselves were less likely to think 
their consumers would value this characteristic (p=0.028). Second, participants that indicated 
they worked in the private sector were more likely to indicate their consumers would prefer 
access to other health professionals employed in the pharmacy over pharmacy staff directing 
individuals to other services (p=0.004). Third, participants identifying with an Aboriginal or 
Torres Strait Islander background themselves perceived their consumers to be more averse to 
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a pharmacy near a GP practice compared to a pharmacy near their home/work and less averse 
to cost (p≤0.01), as opposed to participants who did not identify with an Aboriginal or Torres 
Strait Islander background. Finally, participants who were from Northern Rivers region 
perceived their consumers to be less averse to cost than participants from Logan Beaudesert 
(p=0.009).  
 
(6) Priorities for the provision of pharmacy services 
 
Figures 2 and 3 show the relative strength of preference or priority participants would 
on average give to different service attributes, according to the preferences of consumers and 
carers, and the perception of health professionals, respectively.  The size of the bars 
represents the relative importance of a service improvement (i.e. a gain from the least 
preferred level to a more preferred level), after rescaling the model coefficients such that the 
most preferred service improvement for each model was given 100 points, and the other 
improvements were given a lesser number of points in proportion to their relative importance 
for that sample. The colours of the bars represent the attributes, as per the colour code in 
Figure 4.  
 
 
Figures 2,3,4 about here 
 
On average, consumers and carers placed the highest priority on continued medicines 
supply by a pharmacist rather than having to see a doctor for regular and symptom flare up 
medicines (score 100), which was valued more than one and a half times as much as 
pharmacy location in a one stop health centre instead of their GP practice (score 61) and 
twice as much as having the availability of home delivery in addition to face-to-face pick up 
(score 52). Other characteristics were valued to a lesser extent.  
 
On average, health professionals expected their consumers to place highest priority on 
having a pharmacy located near their home/work (score 100) or in a one stop health centre 
(score 88) rather than at a GP practice. Pharmacy location near home/work was expected to 
be valued one and a half times as much as continued medicines supply for regular and 
symptom flare up medicines (score 67) and more than twice as much as having the 
availability of home delivery in addition to face-to-face pick up (score 42). Other 
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characteristics were expected to be valued to a lesser extent. Thus, whilst the attributes health 
professionals expect their consumers to prefer are largely consistent with actual consumer 
and carer preferences, some inconsistencies in the relative priorities were seen. Notably, 
continued supply was the most important priority for consumers and carers, and pharmacy 
location was perceived to be highest priority by health professionals. 
 
 
Discussion 
 
This study provides evidence about the relative importance of different pharmacy 
service characteristics that are preferred by consumers and carers to assist with the 
management of their chronic condition(s).  A substantial proportion of consumers and carers 
were willing to take up a new service, and one quarter always chose a new pharmacy service 
for every choice set, suggesting that the potential for innovative and well-designed pharmacy 
services to optimise consumer-centred care of chronic condition(s) has not yet been fully 
realised. New pharmacy services were more likely to be taken up by younger consumers and 
carers, those in employment or with a higher level of education, and those with established as 
opposed to newly diagnosed chronic condition(s). The reason these consumer and carer 
subgroups in particular are more likely to take up new services was not explored. However, it 
is possible that these groups are more likely to accept or adopt innovation. It is also possible 
that these groups are underserviced by current Australian pharmacy services. It would 
therefore be important to explore the reasons behind this finding in further studies. 
Nevertheless, this finding is consistent with a previous study in Scotland that also found 
younger people were more likely to take up innovative new services.15  Recognition that 
pharmacy services could alleviate unmet health needs of young New Zealanders 23 has been 
accompanied by calls that new services are youth-friendly and developed in consultation with 
young people.51 Although this population does not currently constitute the bulk of those with 
chronic conditions in most countries, they do represent a group with preventative potential. 
By adequately servicing this population and capitalising on their willingness to try innovative 
pharmacy initiatives, it may be possible to stem the wave of chronic disease costs in future. 
Improvements in pharmacy service characteristics could produce worthwhile benefits, 
particularly for these subgroups. 
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It is notable that continued supply of prescription medicines by a pharmacist after an 
existing prescription runs out, particularly involving a supply of medicines that had been used 
before to manage symptom flare ups, was a high priority characteristic for consumers and 
carers. Pharmacist prescribing has already been implemented to varying extents in a number 
of countries including the United Kingdom, United States, Canada and New Zealand.12, 13, 52 
However, in Australia, pharmacist prescribing initiatives remain very limited, occurring only 
within small pilot study schemes.53 Recent initiatives in Australia have allowed “medication 
continuance” by pharmacists for lipid lowering agents and contraceptive medicines, without a 
written prescription, in specified circumstances.54 However, this initiative is more akin to 
continued dispensing to ensure no break in supply, rather than formal repeat prescribing. 
Previous research has shown consumer preferences to support pharmacist repeat prescribing 
in Scotland,15 and pharmacist independent prescribing in England.16 Our findings provide 
considerable consumer and carer support for the provision of continued supply of regular and 
flare up medicines that have been previously prescribed by a medical practitioner in 
Australia. Obviously, this practice would need to occur under agreed guidelines by 
appropriately trained pharmacists and with regular (i.e. annual) visits and review by the GP. 
 
Expanding roles for health professionals including pharmacists are being driven in 
part by an imperative to find new models of care to sustain the over-burdened health system. 
In many countries, population growth and ageing is leading or expected to lead to pressures 
on the health work force and its capacity to maintain service delivery. This pressure is 
promoting the development of new models of care, for example telehealth, or new strategies 
for more affordable skill mix. In some areas, including Australia in which large population 
segments reside in underserviced rural and remote regions, these pressures are heightened by 
access inequities. Over 4 million (3.3%) GP visits annually in Australia relate to a repeat 
prescription for a medicine that has been used before.11 Some commentators have emphasised 
the potential for expansion of pharmacist roles, for example to include repeat prescribing, as a 
safe and cost-effective strategy to address workforce pressures.11 In Australia, pharmacists 
are generally in support of an expanded prescribing role, 55, 56 although there has been little 
research into the opinions of other stakeholders, including the public.57 This preference study 
provides evidence that a pharmacist supplementary prescribing initiative would likely be 
acceptable for the majority of consumers with chronic condition(s), and indeed may be a 
desirable service for many Australian consumers – particularly younger adults, those in 
employment, frequent medicine users, and those with an established diagnosis. 
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Pharmacy location in a “one-stop health centre” was also highly valued. A health hub 
might be seen as attractive as it provides coordination of services as well as convenience. 
Previous research has also confirmed the desirability of pharmacy as part of a one stop health 
hub as a proactive approach to care, encompassing advice and medication management, 
referral alongside assistance with health system navigation, and even health advocacy.32 
Although the preference for availability of home delivery of medicines was expected, the 
aversion to the availability of medicine pick up without going into a pharmacy, for example 
by “drive thru”, was unexpected, as preliminary work indicated convenience to be a highly 
desirable characteristic.32, 33 The option of “face-to-face pick up or drive thru” was valued 
less on average than face-to-face pick up alone. “Drive-thru” services are routinely provided 
in other markets in Australia (e.g. fast food, alcohol). However, qualitative comments made 
by consumers and carers in response to the survey suggested one reason for not choosing a 
new service pertained to the safety and lack of personal contact associated with drive through 
options.  The findings suggest that although consumers and carers value convenience highly, 
they identify pharmacy and medicines use services, and perhaps health care services more 
generally, as inappropriate commodities for impersonal services.  
 
Despite the majority choosing to take up a new service on one or more occasions, a 
considerable proportion of our sample declined to choose a new service. This preference was 
predominantly explained by three reasons; the existence of high quality person-centred 
services based on positive long-term relationships and continuity, the convenience of existing 
services (in terms of speed and location), and the responsiveness of current services to their 
medication needs, including the reliable provision of medication supply and timely expert 
advice. These reasons mirrored those that were identified as important service characteristics 
in earlier qualitative stages of the larger project within which this study sits.32, 33 It would 
seem that if participants are receiving these three qualities from their current pharmacy, the 
need for innovative services is negated. When compared against these fundamental qualities, 
new services were rarely viewed as an advantage. A strong tendency to favour the status quo 
in healthcare choices has been previously acknowledged,58 and our findings are consistent 
with previous studies indicating a large group of loyal consumers.15, 59 However, previous 
studies have seldom explored the reason for this loyalty. Our findings show that high quality, 
convenient, person-centred pharmacy services that are responsive to consumer and carer 
medicine needs are fundamental requirements for most consumers.   
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The overall consensus between health professional perceptions of consumer needs and 
actual consumer and carer preferences suggests health professionals are largely empathetic to 
what their consumers and carers require in a pharmacy service. By implication, this would 
suggest health professionals have an understanding of consumer and carer preferences, and 
service provision is likely to be largely consistent with consumer and carer desires. It is 
interesting, but perhaps not surprising, that newly qualified health professionals, and those 
who were consumers with chronic condition(s) or carers themselves, were more sympathetic 
to the value consumers placed on continued medicines supply. The key difference between 
health professionals, and consumers and carers was the reverse order of priorities, with 
continued supply being most important for consumers and carers, and convenience of 
location perceived to be most important by health professionals. Both these characteristics 
relate to aspects of easy access. However, consumers and carers valued the convenience 
and/or cost avoidance afforded by eliminating the need for some doctor visits more strongly 
than was perceived to be the case by health professionals. 
 
Strengths of this study include the very rigorous process undertaken to develop the 
DCE survey instrument, and the diversity of the large sample. For example, the high 
representation of participants identifying as Aboriginal or Torres Strait Islander or from a 
Culturally and Linguistically Diverse background, populations that are often under-
represented in research in Australia, is notable. Nevertheless, the extent to which the findings 
can be held to represent those with chronic condition(s) in the general Australian population 
requires confirmation.  There is only very limited relevant and published data available in 
Australia on individuals with chronic condition(s) to which the survey sample can 
meaningfully be compared. Of those reporting a chronic condition(s) in the Australian 
National Health Survey (NHS) 2007-8,42 51.8% were female (current survey 70.1%) and 
16.6% were 65 years or over (current survey 33.6% were 66 years or over). Of subgroups 
with selected chronic conditions in the NHS, 89.5% spoke English as their main language at 
home (96.2% in current survey), and 65.4% were employed in the labour force (27.1% in 
current survey). Therefore females, older adults and those speaking English at home were 
over-represented and the employed were under-represented in the current survey as compared 
to the Australian NHS population with chronic condition(s). However, any comparison of the 
DCE survey sample with the NHS needs to consider the differing aims and selection 
processes for the studies.  The differences in participant characteristics between the current 
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survey and the NHS likely reflects the focussed aim of the current preference study to access 
the opinions of individuals who were extensive users of pharmacy and healthcare services, as 
well as those who were not; whereas, the NHS was a population survey designed to obtain 
national benchmark information on a range of health related issues (including risk factors and 
disability) and to enable the monitoring of trends in health over time.  
 
Regardless, the limited number of participant characteristics that were associated with 
preference for service characteristics in the current study suggests that preferences for 
pharmacy service characteristics are unlikely to change substantially between different 
subgroups of people with chronic condition(s), suggesting that our findings may be 
generalisable to the Australian population with chronic condition(s) and their carers. 
Nevertheless, this study should be repeated in other samples to confirm the findings and 
examine the stability of choices in different sub-samples. Some counter intuitive findings 
emerged from our study, warranting further investigation. Specifically, consumers and carers 
in employment were more averse to service cost than those not in employment. Although 
employment was moderately correlated with income, income was not significantly associated 
with preference heterogeneity around service cost. Thus, it seems possible that those in 
employment may have a greater financial burden associated with their medicines use (as they 
have limited access to concession schemes), than those not in employment and may arguably 
be more cost averse. This assertion requires empirical confirmation. 
 
A limitation of this study was the use of more than one data collection mode. This 
situation is not ideal in that it assumes no systematic effect of the mode on the responses, 
which may not be the case. However, this approach was used to ensure the size and diversity 
of the sample (i.e. access to those who were not easily reached by telephone) and 
convenience for participants. Another limitation was the use of hypothetical discrete choice 
questions in the survey based on the assumption that participants would choose in reality the 
services they indicated. Although DCEs in general make this assumption, the indirect 
elicitation nature of the DCE task has been argued to overcome any hypothetical bias, as 
compared to alternative preference elicitation methods.60 Moreover, the DCE enables 
elicitation of preferences for services including new services for which revealed market 
preference data are not available, as is the case here. MXL requires a distributional 
assumption to be made for the data, and this could be considered a disadvantage of the MXL 
analytic approach. Nevertheless, the assumption of a normal distribution for all random 
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parameters in the MXL analyses is commonly applied in health-related DCEs.29 Finally, our 
comparison of the preferences of consumers and carers with the perceptions of health 
professionals may be limited by the DCE design, in that consumers and carers were offered 
an opt out alternative of their current pharmacy service, whereas health professionals were 
not.  However, this difference was necessary for realism. An opt out was necessary for 
consumers and carers who would not have to take up a new service in reality; whereas, such a 
choice for health professionals who were asked to provide their perception of consumers  
preferred choice would not be sensible (since they have no knowledge of the consumers 
current service). 
 
CONCLUSION 
 
This study emphasises the fundamental importance, from the consumer and carer 
perspective, of the provision of high quality and convenient person-centred pharmacy 
services that are responsive to their needs. Pharmacy can deliver substantially greater benefits 
for consumers with chronic condition(s) and carers through well-designed services that attend 
to these fundamental characteristics. This is particularly the case for younger consumers and 
carers, those in employment, more highly educated, and those with established as opposed to 
newly diagnosed condition(s). Targeting these groups with new and innovative pharmacy 
services that align to their unique needs presents an opportunity for improving the 
management of chronic condition(s) in the community, reducing overall treatment burden. 
The provision of continued medicines supply (e.g. through pharmacist prescribing), 
convenient and coordinated care in a one stop health centre, and home delivery in particular, 
should be prioritised when planning pharmacy services to assist consumers to manage 
chronic conditions. 
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Figure Captions 
 
Figure 1: Indicative choice set (consumer and carer participants) 
 
 
Figure 2: Consumer and carer priorities for pharmacy services 
 
Footnote to Figure 2: 
Bars are colour coded for attributes; order of legend is consistent with order of bars.  
Size of bar represents relative value of a gain in attribute from the least preferred level 
(defined in Figure 4). 
***, ** ==> Relevant parameter (numerator for the rescaled weights) was significant in 
model at 1%, 5% level. 
 
Figure 3: Health professional perception of consumer and carer priorities for pharmacy 
services 
 
Footnote to Figure 3: 
Bars are colour coded for attributes; order of legend is consistent with order of bars.  
Size of bar represents relative value of a gain in attribute from the least preferred level 
(defined in Figure 4). 
***, ** ==> Relevant parameter (numerator for the rescaled weights) was significant in 
model at 1%, 5% level. 
 
Figure 4: Attribute colour coding and least preferred level 
 
Footnote to Figure 4: 
a Least preferred level aids interpretation of Figures 2 and 3 
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Tables 
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Table 1: Attributes and levels, with cross reference to overarching theme 
Theme Attribute How this is described in the DCE choice (i.e. Levels) a 
Innovation (i.e. 
pharmacist 
prescribing) 
Continued 
medicines 
supply 
Pharmacist, but only for regular medicines, and for 
medicines you’ve used  periodically for symptom 
flare-ups, with an annual review by the doctor 
Pharmacist, but only for regular medicines, with an 
annual review by the doctor 
Doctor for all medicines 
Continuity and 
coordinated care 
(i.e. referral and 
integration) 
 
Manage 
ongoing  
condition 
Pharmacy staff available to speak with you and 
direct you  to other  health services, which you can 
then access yourself (e.g. dieticians ) 
You can get advice from other health providers who 
are employed in the pharmacy (e.g. dieticians ) 
Access to pharmacy Pharmacy 
location 
Pharmacy that is located near to your home or work 
but away from other health services 
Pharmacy that is located near to your GP practice 
only 
Pharmacy that is located in a one stop health centre 
with all clinics and services, including your GP 
Medication 
management 
 
Getting your 
medicines 
Face to face pick up at pharmacy 
Face to face pick up at pharmacy and you can 
collect your medicines without going into the 
pharmacy if required (e.g. drive thru) 
Face to face pick up at pharmacy and you can 
request home delivery 
Consumer education 
and information 
 
Medicines 
review or 
advice  
The pharmacist is in the dispensary and you can ask 
to speak to them 
The pharmacist is available in the pharmacy  
without you needing to ask 
The pharmacist is available in the pharmacy without 
you needing to ask and you can speak to the 
pharmacist by phone, email, or internet 
The pharmacist is available in the pharmacy without 
you needing to ask and you can make an 
appointment for the pharmacist to visit you at home 
Affordability (i.e. 
cost of service, 
additional to cost of 
medicines) 
Average cost 
per month 
$0 per month 
$10 per month 
$20 per month 
a Wording shown is for consumer and carer survey; attributes and levels were the same for 
health professionals, but wording was amended to ask what service they thought their 
consumers would prefer.  
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Table 2: Characteristics of consumer and carer participants 
Characteristic Level Total a  
(n= 602)  
 
 n % 
Consumer carer 
status 
Consumer only 442 73.4 
 Carer only 21 3.5 
 Both consumer and carer 139 23.1 
Unpaid carer Has an unpaid carer 137 23.7 
Region Logan Beaudesert 236 39.2 
 Mt Isa & North West 42 7.0 
 Northern Rivers 191 31.7 
 Greater Perth 133 22.1 
Gender Female 422 70.1 
Age (years) ≤25 22 3.7 
 26-40 81 13.5 
 41-65 295 49.2 
 ≥66 202 33.6 
Cultural 
background 
Australian (non-indigenous) 368 61.2 
 Aboriginal or Torres Strait Islander 54 9.0 
 Other (inc. Culturally and Linguistically Diverse) 179 29.8 
Main language 
spoken at home 
English  579 96.2 
Marital status Has a partner (married or defacto) 322 53.5 
Education Highest educational attainment primary or secondary 
school 
251 41.7 
Employment status Employed (part time, full time, casual) 163 27.1 
Household income ≤$50k per annum 363 60.5 
 >$50,000 per annum 180 30.0 
 Prefer not to say 57 9.5 
Community 
pharmacy loyalty 
Usually visits one community pharmacy most of the 
time 
414 68.9 
Community 
pharmacy 
frequency 
Visit community pharmacy fortnightly or more often 339 56.3 
GP visit frequency Visit GP monthly or more often 316 55.1 
QoL (EQ-5D-3L) b Higher QoL (>0.65) 345 57.4 
Treatment burden c Higher treatment burden (>60/150) 247 42.0 
Recent diagnosis  Consumer with one or more recently diagnosed 
(≤6mths) chronic condition(s) 
37 6.6 
Medicines use – 
number 
Consumer taking ≥7 different medicines (including 
prescription medicines, OTC and vitamins) per day 
247 41.2 
Medicines 
frequency – times 
per day 
Consumer taking medicines ≥3 different times per 
day 
234 39.3 
QoL quality of life, WA Western Australia 
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a Age, cultural background, educational qualification, GP frequency, household income, 
medicines use (number and frequency per day), pharmacy loyalty, QoL, recent diagnosis, 
treatment burden, and unpaid carer had small proportions of missing/incomplete data. 
Percentages are based on actual number of individual responses. 
bEQ-5D-3L utility weights assigned using the Australian tariff.40 
cTreatment burden assessed using an adapted scale published by Tran et al. 41 
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Table 3: Characteristics of health professional/health worker participants 
Characteristic Level 
 
Totala 
(n=297) 
 
 n % 
Health professional/ 
worker role 
Pharmacist 89 30.0 
 Doctor (GP or specialist) 40 13.5 
 Nurse 60 20.2 
 Other, including allied health and health worker 108 36.4 
Region Logan Beaudesert 168 56.6 
 Mt Isa & North West 20 6.7 
 Northern Rivers 51 17.2 
 Greater Perth 58 19.5 
Gender Female 230 77.4 
Age (years) ≤25 28 9.5 
 26-40 116 39.3 
 41-65 147 49.8 
 ≥66 4 1.4 
Cultural background Australian (non-indigenous) 172 57.9 
 Aboriginal or Torres Strait Islander 10 3.4 
 Other (inc. Culturally and Linguistically Diverse) 115 38.7 
Main language spoken at 
home 
English  260 87.8 
Employment sector Hospital 32 11.0 
 General practice 48 16.6 
 Primary care 45 15.5 
 Community/home-based care 129 44.5 
 Other b 36 12.4 
Industry sector Private 121 41.7 
 Public or Not for profit 162 55.9 
 Other 7 2.4 
Time in profession <5 years 83 28.9 
 ≥5 years 204 71.1 
Consumer carer status Consumer only 46 15.6 
 Carer only 55 18.6 
 Both consumer and carer 19 6.4 
 Neither consumer nor carer 175 59.3 
a Age, consumer and carer status, language spoken at home, sector of employment and time in 
profession, had small proportions of incomplete and/or missing data. Percentages are based 
on actual number of individual responses 
b Other includes research, mental health, education and training. 
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Table 4: Most common reasons given for choosing current pharmacy service from 
thematic analysis 
Reason for choosing current pharmacy service Number of times reason 
given a 
Current service offered continuity through long-term knowledge 
about his or her needs and personal relationships with staff 
members 
188  
Current service friendly and helpful 161 
Located in a convenient place 148 
Preferred characteristics of new service already offered by 
current service 
97 
Not prepared to pay for new service and/or current service high 
quality for no cost 
95 
Current service was perceived to be a good source of advice, 
guidance, information and discussion about medications or 
symptoms that could not be replicated elsewhere 
92  
Current service flexible, reliable and timely source of medication 
supply, particularly in times of emergency 
53  
 New services not needed at all or not appropriate for needs, or 
some small aspects were valued 
 
26  
New services were not  appropriate for delivery within or by 
pharmacy 
21  
Speediness of current service (short/no wait)  16  
No reason was stated for opting out 10  
a Total of 907 reasons were given by 471 consumers and carers who chose their current 
service for at least one scenario. 
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Table 5:  Mixed Logit (MXL) model of consumer and carer preferences 
Attribute Level Coefficient P b 
Random and Non-random Parameters 
Constant Current service  *** 2.048 ≤0.001 
Continued medicines supply Doctor for all -0.420 
Pharmacist for regular 0.063 0.725 
Pharmacist for regular and symptom flare *** 0.357 ≤0.001 
Manage ongoing condition 
Health professionals employed in 
pharmacy 0.071 
Pharmacy staff direct to services -0.071 0.111 
Pharmacy location Near home/work -0.081 
Near GP practice *** -0.196 0.005 
One stop health centre *** 0.278 ≤0.001 
Getting your medicines Face to face pick up pharmacy -0.088 
Face to face pick up pharmacy and home 
delivery *** 0.246 0.001 
Face to face pick up pharmacy and collect 
e.g.drive thru ** -0.158 0.025 
Medicines review or advice Dispensary, ask to speak 0.092 
Pharmacy, no need to ask -0.119 0.183 
Dispensary, and by phone, email, internet 0.104 0.254 
Dispensary, and by appointment at home -0.077 0.416 
Average cost per month Additional $1 increase in cost *** -0.064 0.002 
Heterogeneity in Mean, Parameter: Variable a 
Current pharmacy service: Age ≤ 25 yrs *** -1.796 0.008 
Current pharmacy service: Age ≥66 yrs *** 1.883 ≤0.001 
Current pharmacy service: Employed ** -0.562 0.023 
Current pharmacy service: Usually visit one pharmacy *** 0.818 ≤0.001 
Current pharmacy service: Primary/Secondary education ** 0.482 0.026 
Current pharmacy service: Recent diagnosis (≤6 mths) ** 1.118 0.010 
Current pharmacy service: Perth region ** 0.935 0.023 
Pharmacist for regular medicines: Recent diagnosis (≤6 mths) ** -0.302 0.040 
Pharmacist for regular medicines: Medicine ≥ 3 times per day *** 0.198 0.008 
Cost: Employed *** -0.032 0.001 
Cost: Mt Isa & North West region *** 0.065 0.002 
Distributions of Random Parameters (Standard Deviations) 
Constant Current service  *** 3.968 ≤0.001 
Continued medicines supply Pharmacist for regular  *** 0.476 0.002 
Average cost per month Additional $1 increase in cost *** 0.074 ≤0.001 
a
 Only 11 significant of 30 parameters shown (remainder not significant at 5% level). 
b
 P value: ***, ** ==>  Significance at 1%, 5% level. 
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Table 6:  Mixed Logit (MXL) model of health professional perception of preferences 
Attribute 
Level 
 Coefficient P value 
Random and Non-random Parameters 
Continued medicines supply Doctor for all 
 
-0.460 
Pharmacist for regular 0.067 0.396 
Pharmacist for regular and symptom flare 0.393 0.075 
Manage ongoing condition Health professionals employed in pharmacy 0.052 
Pharmacy staff direct to services -0.052 0.723 
Pharmacy location Near home/work 0.477 
Near GP practice *** -0.805 ≤0.001 
One stop health centre *** 0.328 ≤0.001 
Getting your medicines Face to face  pick up pharmacy -0.198 
Face to face  pick up pharmacy  and home 
delivery *** 0.337 ≤0.001 
Face to face  pick up pharmacy  and collect 
e.g. drive thru -0.139 0.085 
Medicines review or advice Dispensary, ask to speak -0.202 
Pharmacy, no need to ask 0.048 0.657 
Dispensary, and by phone, email, internet 0.117 0.303 
Dispensary, and by appointment at home 0.037 0.734 
Average cost per month per $1 increase -0.024 0.393 
Heterogeneity in Mean Parameter: Variable a 
Pharmacist for regular and symptom flare medicines: Not consumer or carer ** -0.206 0.028 
Pharmacist for regular and symptom flare medicines: Time in profession <5 yrs *** 0.221 0.009 
Pharmacy staff direct to other services: Private sector *** -0.154 0.004 
Location near GP practice: Aboriginal or Torres Strait Islander *** -0.628 0.007 
Cost: Northern Rivers region *** 0.034 0.009 
Cost: Aboriginal or Torres Strait Islander *** 0.076 0.006 
Distributions of Random Parameters (Standard Deviations) 
Continued medicines supply Pharmacist for regular and symptom flare ** 0.416 0.027 
Manage ongoing condition Pharmacy staff direct to services 0.133 0.596 
Pharmacy location Near GP practice *** 0.584 ≤0.001 
Average cost per month per $1 increase *** 0.108 ≤0.001 
a
 Only 6 significant of 20 parameters shown (remainder not significant at 5% level). 
b
 P value: ***, ** ==>  Significance at 1%, 5% level. 
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Which new pharmacy service would you prefer to help you to manage your ongoing health condition and/or the 
condition of the person you care for? (Please select whether you would prefer Service A or Service B) 
 
 
Services offered at the 
pharmacy 
 
 Service A Service B 
 
 
  
When you run out of your 
prescription medicines, you need 
to go to 
 
Doctor for all medicines 
Pharmacist, but only for regular 
medicines, and for medicines you’ve 
used periodically for symptom flare-
ups, with an annual review by doctor 
Help to manage ongoing health 
condition(s)  
 Pharmacy staff available to speak 
with you and direct you to other 
health services, which you can then 
access yourself (e.g. dieticians) 
You can get advice from other health 
providers who are employed in the 
pharmacy (e.g. dieticians) 
Pharmacy location  
 Pharmacy that is located near to your 
GP practice only 
Pharmacy that is located near to your 
home or work but away from other 
health services 
Getting your medicines  
 
Face to face pick up at pharmacy 
Face to face pick up at pharmacy and 
you can collect your medicines 
without going into the pharmacy if 
required (e.g. drive thru) 
Medicines review or advice  
 The pharmacist is available in the 
pharmacy without you needing to ask 
and you can make an appointment for 
the pharmacist to visit you at home 
The pharmacist is available in the 
pharmacy without you needing to ask 
and you can speak to the pharmacist 
by phone, email or internet 
Average cost per month   $10 per month $20 per month 
 
   
Choice Set One: 
If these were the only two 
pharmacy services available to 
you, which service would you 
prefer to use? 
 
 
 
Service A 
 
 
Service B 
Choice Set One: 
Would you choose your 
preferred service described 
above or your usual pharmacy 
service? 
 
   I would choose my preferred new pharmacy service 
    I would stay with my usual pharmacy service 
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  Key for Figure Bars Least preferred level a 
  Continued medicines supply Doctor for all 
  
Pharmacy location Near GP practice 
  Getting your medicines 
Face to face pick up pharmacy and collect e.g. drive 
thru (consumers and carers) 
Face to face pick up pharmacy (health professionals) 
  Medicines review or advice Pharmacy, no need to ask (consumers and carers) Dispensary, ask to speak (health professionals) 
  Manage ongoing condition Pharmacy staff direct to services 
  Average cost per month Per $1 increase 
 
